Health Group Challenges Gilead Patents In The US On Grounds Of Lack Of Novelty
A health advocacy group today announced that it has challenged a set of United States patents for a hepatitis C medicine. The group says drug maker Gilead Sciences has obtained unmerited patents for sofosbuvir, blocking millions of US patients from affordable treatment.







